The focus of Dr. Rosenstein’s research program is the identification of single nucleotide polymorphisms (SNPs) associated with the development of adverse effects resulting from radiotherapy. This work has been supported by grants from NIH/NCI, the DOD Prostate Cancer Research Program and the American Cancer Society. In this context, Dr. Rosenstein established and has led the Gene-PARE (Genetic Predictors of Adverse Radiotherapy Effects) consortium consisting of 15 investigators from 5 countries to collaborate on projects in radiogenomics. Dr. Rosenstein’s group was among the first to hypothesize that possession of SNPs in certain genes may render some patients more susceptible to injuries resulting from radiotherapy. During the early years of this project, the main approach involved genotyping DNA samples derived from cancer patients treated with radiotherapy for SNPs in a limited number of candidate genes associated with radiation response. However, in recent years, the focus has shifted to a genome wide approach and his group was the first to publish a genome wide association study (GWAS) to identify SNPs associated with radiotherapy response. Dr. Rosenstein has expanded this research and work is in progress to genotype approximately 3,000 additional prostate cancer patients treated with radiotherapy from five validation cohorts to determine which SNPs specifically validate across multiple cohorts. Three years ago, Dr. Rosenstein established and has co-led the Radiogenomics Consortium (RGC) with Dr. Catharine West, representing an international consortium with 122 members from 67 institutions in 18 countries. The overall goal of the RGC is to develop a collaborative infrastructure to permit the large scale discovery GWAS and validation studies that are essential for the identification of genetic factors associated with response to radiotherapy and to develop assays to predict radiation response. Currently, there are six major collaborative studies being conducted by the RGC.
West CM, Dunning AM, Rosenstein BS. Genome-wide association studies and prediction of normal tissue toxicity. Seminars in radiation oncology 2012 Apr; 22(2).
Kelsey CR, Rosenstein BS, Marks LB. Predicting toxicity from radiation therapy-It's genetic, right?. Cancer 2011 Dec;.
Ko EC, Forsythe K, Buckstein M, Kao J, Rosenstein BS. Radiobiological rationale and clinical implications of hypofractionated radiation therapy. Cancer radiothérapie : journal de la Société française de radiothérapie oncologique 2011 Jun; 15(3).
Cuaron JJ, Hirsch AE, Medich DC, Hirsch JA, Rosenstein BS. Introduction to radiation safety and monitoring. Journal of the American College of Radiology : JACR 2011 Apr; 8(4).
Rosenstein BS. Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy. Pharmacogenomics 2011 Feb; 12(2).
Stone NN, Stone MM, Rosenstein BS, Unger P, Stock RG. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. The Journal of urology 2011 Feb; 185(2).
Kerns SL, Ostrer H, Stock R, Li W, Moore J, Pearlman A, Campbell C, Shao Y, Stone N, Kusnetz L, Rosenstein BS. Genome-wide association study to identify single nucleotide polymorphisms (SNPs) associated with the development of erectile dysfunction in African-American men after radiotherapy for prostate cancer. International journal of radiation oncology, biology, physics 2010 Dec; 78(5).
Bernstein JL, Haile RW, Stovall M, Boice JD, Shore RE, Langholz B, Thomas DC, Bernstein L, Lynch CF, Olsen JH, Malone KE, Mellemkjaer L, Borresen-Dale AL, Rosenstein BS, Teraoka SN, Diep AT, Smith SA, Capanu M, Reiner AS, Liang X, Gatti RA, Concannon P. Radiation exposure, the ATM Gene, and contralateral breast cancer in the women's environmental cancer and radiation epidemiology study. Journal of the National Cancer Institute 2010 Apr; 102(7).
Bentzen SM, Parliament M, Deasy JO, Dicker A, Curran WJ, Williams JP, Rosenstein BS. Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. International journal of radiation oncology, biology, physics 2010 Mar; 76(3 Suppl).
Azria D, Belkacemi Y, Romieu G, Gourgou S, Gutowski M, Zaman K, Moscardo CL, Lemanski C, Coelho M, Rosenstein B, Fenoglietto P, Crompton NE, Ozsahin M. Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial. The lancet oncology 2010 Mar; 11(3).
West C, Rosenstein BS. Establishment of a radiogenomics consortium. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2010 Jan; 94(1).
Stone NN, Cesaretti JA, Rosenstein B, Stock RG. Do high radiation doses in locally advanced prostate cancer patients treated with 103Pd implant plus external beam irradiation cause increased urinary, rectal, and sexual morbidity?. Brachytherapy; 9(2).
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr.Rosenstein did not report having any of the following types of financial relationships with industry during 2015 and/or 2016: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.